FHI Clinical collaborating with Tactical Therapeutics, Inc., to refine the protocol for the development of carboxyamidotriazole orotate (CTO) to treat respiratory diseases
December 21, 2022
FHI Clinical is contributing to the protocol design for a Phase 2 clinical trial to evaluate carboxyamidotriazole orotate (CTO), an asset from Tactical Therapeutics.